Arcturus Therapeutics Holdings Financial Statements (ARCT)
|
|
|
|
Report date
|
|
|
29.03.2023 |
31.12.2023 |
14.03.2024 |
06.03.2025 |
03.03.2026 |
|
03.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
205.8 |
169.9 |
157.7 |
138.4 |
67.2 |
|
74.1 |
|
Operating Income, bln rub |
|
|
12.2 |
-75.1 |
-78.2 |
-95.7 |
-75.0 |
|
-75.0 |
|
EBITDA, bln rub |
? |
|
13.7 |
-75.1 |
-24.2 |
-77.4 |
-71.9 |
|
-71.7 |
|
Net profit, bln rub |
? |
|
9.35 |
-26.6 |
-29.7 |
-80.9 |
-65.8 |
|
-65.8 |
|
|
OCF, bln rub |
? |
|
32.0 |
|
-18.1 |
-59.7 |
-74.3 |
|
-74.3 |
|
CAPEX, bln rub |
? |
|
7.73 |
|
2.90 |
0.648 |
0.230 |
|
0.456 |
|
FCF, bln rub |
? |
|
24.3 |
|
-21.0 |
-60.4 |
-74.3 |
|
-74.7 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
193.6 |
245.0 |
236.0 |
234.1 |
139.2 |
|
139.2 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
3.03 |
|
4.02 |
|
R&D, bln rub |
|
|
147.8 |
192.1 |
192.1 |
195.2 |
112.2 |
|
112.2 |
|
Interest expenses, bln rub |
|
|
3.00 |
0.000 |
0.767 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
450.4 |
429.4 |
429.4 |
344.1 |
271.1 |
|
271.1 |
|
Net Assets, bln rub |
? |
|
270.3 |
281.6 |
278.5 |
241.0 |
214.0 |
|
214.0 |
|
Debt, bln rub |
|
|
94.8 |
25.9 |
30.2 |
28.6 |
25.0 |
|
25.0 |
|
Cash, bln rub |
|
|
391.9 |
347.0 |
292.0 |
237.0 |
230.9 |
|
230.9 |
|
Net debt, bln rub |
|
|
-297.1 |
-321.1 |
-261.8 |
-208.5 |
-205.9 |
|
-205.9 |
|
|
Ordinary share price, rub |
|
|
17.0 |
31.5 |
31.5 |
17.0 |
6.13 |
|
8.90 |
|
Number of ordinary shares, mln |
|
|
26.4 |
26.6 |
26.6 |
27.0 |
27.4 |
|
27.4 |
|
|
Market cap, bln rub |
|
|
449 |
840 |
840 |
458 |
168 |
|
244 |
|
EV, bln rub |
? |
|
151 |
518 |
578 |
250 |
-38 |
|
38 |
|
Book value, bln rub |
|
|
270 |
282 |
279 |
241 |
214 |
|
214 |
|
|
EPS, rub |
? |
|
0.35 |
-1.00 |
-1.12 |
-3.00 |
-2.40 |
|
-2.40 |
|
FCF/share, rub |
|
|
0.92 |
0.00 |
-0.79 |
-2.24 |
-2.71 |
|
-2.73 |
|
BV/share, rub |
|
|
10.2 |
10.6 |
10.5 |
8.93 |
7.81 |
|
7.81 |
|
|
EBITDA margin, % |
? |
|
6.66% |
-44.2% |
-15.3% |
-55.9% |
-107.0% |
|
-96.7% |
|
Net margin, % |
? |
|
4.54% |
-15.6% |
-18.8% |
-58.5% |
-97.9% |
|
-88.7% |
|
FCF yield, % |
? |
|
5.41% |
0.00% |
-2.50% |
-13.2% |
-44.2% |
|
-30.7% |
|
ROE, % |
? |
|
3.46% |
-9.44% |
-10.7% |
-33.6% |
-30.7% |
|
-30.7% |
|
ROA, % |
? |
|
2.08% |
-6.19% |
-6.92% |
-23.5% |
-24.3% |
|
-24.3% |
|
|
P/E |
? |
|
48.0 |
-31.6 |
-28.2 |
-5.66 |
-2.55 |
|
-3.71 |
|
P/FCF |
|
|
18.5 |
|
-40.0 |
-7.59 |
-2.26 |
|
-3.26 |
|
P/S |
? |
|
2.18 |
4.94 |
5.32 |
3.31 |
2.50 |
|
3.29 |
|
P/BV |
? |
|
1.66 |
2.98 |
3.01 |
1.90 |
0.78 |
|
1.14 |
|
EV/EBITDA |
? |
|
11.0 |
-6.91 |
-23.9 |
-3.23 |
0.53 |
|
-0.53 |
|
Debt/EBITDA |
|
|
-21.7 |
4.28 |
10.8 |
2.69 |
2.86 |
|
2.87 |
|
|
R&D/CAPEX, % |
|
|
1 912% |
|
6 623% |
30 117% |
48 788% |
|
24 626% |
|
|
CAPEX/Revenue, % |
|
|
3.75% |
0.00% |
1.84% |
0.47% |
0.34% |
|
0.61% |
|
| Arcturus Therapeutics Holdings shareholders |
